Topic: How To Invest

Hello Pat. I would appreciate your opinion on Allos Therapeutics Inc.

Article Excerpt

Allos Therapeutics, $2.87, symbol ALTH on Nasdaq (Shares outstanding: 105.6 million; Market cap: $303.0 million; www.allos.com), is a drug company that is aiming to develop cancer treatments. Allos is focused on developing and selling its Folotyn drug. In September 2009, Folotyn was approved for treating patients with relapsed or refractory peripheral T-cell lymphoma. Clinical trials have proven that the drug is the most effective on the market. Allos is also testing Folotyn to determine if it will be effective against certain lung cancers, as well as breast cancer and bladder cancer. Even so, Folotyn’s sales were only $11.7 million in the three months ended December 31, 2010, up from $3.6 million a year earlier. The company lost $18.1 million, or $0.17 a share, in the latest quarter, compared to a loss of $22.9 million, or $0.22 a share. The company doesn’t have a large salesforce to market Folotyn; that’s why the drug’s sales are low. As well, it’s proving difficult to convince doctors…